Objective Various antiviral therapies, including interferon therapy, are being conducted to treat chronic hepa-
Introduction
Because only approximately 10%of patients with interstitial pneumonia (IP) test positive for the HCVantibody (1), HCVmay not necessarily cause interstitial pneumonia (IP), but IP has been considered as an extrahepatic complication of HCV-associated chronic disease. In addition, while HCV induces fibrosis in the liver, because the underlying condition of IP is pulmonary fibrosis, HCVmay correlate with IP. Furthermore, there have been reports of IP caused by drugs used in the treatment of liver disease. Of the various drugs used in the treatment of liver disease, Sho-sai-koto has been shown to cause IP (2) , and because interferon has been actively used in the treatment of chronic hepatitis C, IP caused by interferon has attracted attention in recent years (3) . Interferon is essential in improving the QOLof patients with HCV-associated chronic disease. As a result, it is extremely important to be able to predict the onset of IP in order to provide proper care for patients with HCVassociated chronic disease. In this study, we measured the level of KL-6, a serum marker for IP, to determine whether KL-6, an Interstitial Pneumonia Marker, as a Possible Hepatic Fibrosis Marker KL-6 could serve as a predictive factor for IP and to investigate the clinical significance of KL-6 in HCV-associated chronic disease.
Subjects and Methods

Subjec ts
The subjects were 308 patients and inpatients with HCVassociated chronic disease whowere treated at the Department of Gastroenterology and Hepatology, University measured. The level of serum KL-6 was measured using A TEST KL-6 (Eisai, Tokyo). When the level of KL-6 was above a cut-off value of 500 U/ml, chest CTwas performed on consenting patients, and CTscans were examined for IP by radiologists.
Statistical analysis
Values were expressed as mean±S.D. Comparison between two groups was analyzed using unpaired t-test.
Variable frequency was compared using Fisher's exact test.
Correlations between each variable were tested using Pearson' s correlation coefficient. To evaluate the association between high serum KL-6 (>500 U/ml) and potential risk factors, odds ratio and corresponding 95%CI were computed by means of unconditional logistic regression models. A value of p<0.05 was considered statistical significant.
Results
Serum KL-6 levels in HCV-associated chronic disease Of the 308 patients, 4 patients had IP. Figure 1 shows the serum KL-6 level for 304 patients without IP. The mean KL-6 level for the 184 patients with chronic hepatitis C was 283.5+131.4 U/ml, while that for the 120 patients with liver cirrhosis was significantly higher, at 377.6±212.1 U/ml (p<0.0001). In addition, the severity of liver cirrhosis was assessed according to Child's classification system into two groups: Grade A and Grade B/C. The KL-6 level for 86 patients (Grade A) was 334.0±177.8 U/ml, while that for 54 patients (Grade B/C) was significantly higher, at 425.9±220.2 U/ml (p=0.0081). The ratio of patients with a KL-6 level above the cut-off value was 5.41% (10/185) for the chronic hepatitis-C patients, while that for the cirrhotic patients was significantly higher, at 20.33% (25/123) (p<0.0001).
Correlation to hepatic fibrosis markers In order to clarify the correlation between KL-6 and advances in HCV-associated chronic diseases, particularly hepatic fibrosis, the level of two hepatic fibrosis markers, hyaluronic acid (HA) and Type III procollagen N-terminal peptide (P-III-P), was measured (Fig. 2) . The mean serum KL-6 level for the 113 patients with a serum HAlevel of less p<0.0001 p=0.0718 than 100 ng/ml was 258.4±124.6 U/ml, while that for the 144 patients with a serum HAlevel of 100 ng/ml and above was significantly higher, at 381.0+197.3 U/ml (p<0.0001). In addition, the mean serum KL-6 level for the 150 patients with a serum P-III-P level of less than 1.5 U/ml was 332.8+179.1 U/ml, while that for the 10 patients with a serum P-III-P level of more than 1.5 U/ml was 439.9±208.2 U/ml, but there was no significant difference between the two groups (p=0.0718).
Serum HAand KL-6 levels With patients who might have had IP (serum KL-6: >500 U/ml) excluded, the close relationship between serum HA and KL-6 was investigated (Fig. 3) . A significant positive correlation was found between serum HA and KL-6 (p=0.0002).
Chronic liver disease markers related to KL-6 KL-6is a glycoprotein antigen that was once used as a lung cancer marker, but is currently being used as an IP one. As a result, a logistic analysis was performed amongpatients with chronic liver disease to potential risk factors related to serum KL-6 (Tables 1 and 2 ). Amongthe 304 patients with HCV-associated chronic disease without IP, a univariate analysis was performed, and the results showed that the OR for demonstrating high serum KL-6 (>500 U/ml) was 5. Serum KL-6 and hyaluronic acid levels In patients with HCV-associated chronic disease with IP Of the 308 patients, 4 patients had HCV-associated chronic disease complicated by IP (Table 3) . One patient was taking Sho-sai-koto, and while it was not clear whether this drug caused interstitial pneumonia,the other three patients were not taking any medication that could have induced IP. Of the 4 patients with IP, the level of serum KL-6 was above the cut-off value in 2 patients (50%). The level of serum KL-6 was markedly high in 1 patient, and was below the cut-off value in 2 patients.
Changes in KL-6 in a patient with a high KL-6 level before interferon therapy Of the 14 patients receiving interferon therapy, the level of serum KL-6 was high before interferon therapy in 1 patient. Figure 4 shows the chronological changes in the levels of serum KL-6 and HAin this patient. After the interferon therapy, the levels of serum KL-6 and HAdecreased during progress, and although chest CT was performed twice, no clear signs of IP were seen.
Discussion
Although hepatocellular carcinoma and esophageal varices are widely recognized as complications associated with HCV-associated chronic disease, IP has not been well recognized as an extrahepatic complication associated with hepatitis-C virus infection, due to its low incidence. Ever since Sho-sai-koto, a drug that was once widely used in the treatment of HCV-associated chronic disease, was reported to cause IP, there has been greater interest in drug-induced IP. In addition, in recent years, interferon has been actively administered to patients with chronic hepatitis C in order to prevent cancer, and interferon-induced IP is attracting greater attention as a result. While the incidence of interferon-induced IP is low (0.4%, 3/677) (5), it is one of the clinically significant adverse reactions associated with this therapy. Therefore, it is clinically useful to be able to predict the onset of drug-induced IP when administering Sho-saikoto or interferon to patients with chronic hepatitis C. As far as drug-induced IP is concerned, one clinical study on Shosai-koto reported increased lymphocytes and neutrophils and a decreased CD4/8 ratio in the bronchoalveolar lavage fluid (BALF) (4) . In addition, one study found that the incidence of IP among patients with hepatitis-C virus infection (8/66, 12.2%) was higher than that among healthy volunteers (3.66%) (1), thus suggesting a close relationship between hepatitis-C virus infection and IP. Another study analyzed the BALFof patients with chronic hepatitis C, and reported that while the total cell count and the numberof lymphocytes for the hepatitis patients were higher than those for healthy individuals, there was no significant difference in CD4/8 ratio (6). These BALFfindings were similar to those associated with drug-induced IP. This data suggests that patients with hepatitis-C virus infection are prone to IP, and that allergic reactions to a drug can induce IP in some patients. KL-6, a glycoprotein antigen discovered by Kohno et al (7) , and that is currently being used as an IP marker. In addition, KL-6 is a monoclonal antibody (IgGl) that recognizes the carbohydrate section of a glycoprotein antigen, which is expressed abundantly in type-II alveolar epithelial cells (7), is a potent chemotactic factor for fibroblasts (8) , and facilitates pulmonary fibrosis. Furthermore, the level of KL-6 in the BALFof interstitial pneumonia patients was significantly higher than that of healthy control subjects (9) and, with interstitial pneumonia, when alveolar epithelial, basal, and endothelial cells are damaged, the air-blood barrier is compromised and, when permeability accelerates, KL-6/MUC1
is absorbed into the blood, thus elevating its serum concentration. However, in the present study, the level of serum KL-6 for the liver cirrhosis patients was significantly higher than that for the chronic hepatitis patients and, when liver cirrhosis was classified according to Child's system, the level of serum KL-6 for the Child B/C patients was significantly higher than that for the Child A patients, thus suggesting a correlation between KL-6 and liver disease. In addition, serum HAis a marker that reflects the severity of hepatic fibrosis (10), and there was a significantly positive correlation between HAand KL-6. Furthermore, P-III-P is a marker that reflects fibrosis progression, but is not a marker for the grading of fibrosis in the hepatic tissue. As the level of serum KL-6 was high among patients with a high level of serum P-III-P and there was a positive correlation between HAand KL-6, it appears that high KL-6 is correlated with increased fibrosis progression and hepatic fibrosis. In the present study on HCV-associated chronic disease, the ratio of patients with a serum KL-6level above the cut-off value was ll.4% (35/304), which was clearly higher than a healthy volunteer reported by Kobayashi et al (1.83%, 5/273) (ll) . Among the 35 patients with a serum KL-6 level above the cut-off value, only 4 patients showed clear signs of IP and, as the incidence of IP amongpatients with a serum KL-6 level above the cutoff value has been reported at 81%, the incidence of IP Internal Medicine Vol. 42, No. 8 (August 2003) amongthe patients with HCV-associated chronic disease was clearly lower. These findings suggest that KL-6 in patients with HCV-associated chronic disease reflects hepatic fibrosis better than pulmonary fibrosis. Amongthe patients receiving interferon therapy, the level of serum KL-6 was high in one patient before therapy and, in this patient, the levels of serum HAand KL-6 decreased following the therapy. In addition, this patient did not have the complication of IP during the study. Therefore, in order to clarify the use of KL-6as a predictive factor for interstitial pneumonia, it will be necessary to follow patients taking interferon and patients in stable condition for an extended period.
